clinical trial · NCT03618550
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Hodgkin LymphomaRelapsed or Refractory Hodgkin Lymphomapembrolizumabgemcitabinevinorelbineliposomal doxorubicinStem cell mobilization and collection
brief summary
The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.
started
Aug 1, 2018
primary completion
Aug 1, 2026
completion
Aug 1, 2026
last updated
Jun 17, 2026
official title
Phase II Study of Second-line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol